Delanterone is an antiandrogen steroid, developed by the Dutch company Gist-Brocades N.V. for the treatment of various dermatological disorders, including hirsutism, acne, seborrhea, alopecia androgenetica, and baldness. The compound is claimed to show topical anti-androgenic activity with very weak systemic anti-androgenic activity, a lack of progesterone, anti-gonadotrophin and corticosteroid-like activity and very low toxicity.

Lilopristone (ZK 98.734) has a high affinity for progesterone receptors. The progesterone antagonistic effects of ZK 98.734 could be a result of the decrease in progesterone synthesis by the corpus luteum and/or placenta in addition to the interference with the progesterone binding to its cellular receptors in the target organ. ZK 98.734 has potential for fertility regulation. It is a very potent abortifacient in the common marmosets. Lilopristone could significantly suppress the proliferation of ectopic stromal cells in a time- and dose-dependent manner in vitro. The action mechanisms may be associated with the suppression of expression of NF-kappaB P65 mRNA and NF-kappaB P65.

Cloxestradiol is a chlorinated derivative of estradiol, invented by Danish company Leo Pharma AS in 1963. The compound is claimed to have estrogenic activity, as was demonstrated by the extended duration of oestrus caused by the injection of cloxestradiol to castrated female rats.

Bolazine is a synthetic anabolic steroid that uses as the ester prodrug bolazine capronate.

Norvinisterone (Nor-Progestelea) is a progestin and androgen/anabolic steroid (AAS) drug. It appeared to be quite androgenic. It was used in Europe but is no longer marketed.

Domoprednate is a corticosteroid, a glucocorticoid, with anti-inflammatory and anti-allergic properties. Domoprednate is inferior to betamethasone valerate in the same category of dermatoses and equally well tolerated. It can be characterized as a medium-active corticosteroid. Domoprednate can be used topically in the treatment of skin disorders, such as eczema, psoriasis and atopic dermatitis.

Cismadinone is a progestogen steroid.

Tarazepide is a cholecystokinin-A receptor (CCK-A) receptor antagonist that was studied as an antispasmodic agent. However, information about the current use of this drug is not available.

Sufugolix (TAK-013 or 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione) is a highly potent and orally active non-peptide antagonist of luteinizing hormone-releasing hormone (LHRH) receptor. Sufugolix by oral administration suppresses a pituitary-ovarian axis continuously and reversibly in cynomolgus monkeys. Takeda studied Sufugolix in the trials for the treatment of endometriosis and uterine leiomyoma however development was discontinued.